Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide likely benefit or likely lack of benefit for the disease.

The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1.sup.+ cells and/or progeny thereof and/or soluble factors derived therefrom.

The present invention describes a non-invasive system and method for detecting early stage Alzheimer's and other autoimmune diseases associated with neurological deficits, including Multiple Sclerosis and Parkinson's Disease. By analyzing the volatile organic compounds (VOCs) found in the otic canal either in gaseous form or as what is commonly known as “earwax”, the current invention discloses how these disease signatures/profiles are illustrative of the presence or absence of a particular disease.

The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.

The invention provides anti-Tau antibodies and methods of using the same.

CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.

The present invention concerns a DNA-replication-associated (Rep) protein comprising an amino acid sequence as depicted in SEQ ID NO: 11 or 12; (b) a fragment of SEQ ID NOs:11 or 12 which is capable of binding an anti-Rep antibody specific for a protein having the amino acid sequence of SEQ ID NOs: 11 or 12; or (c) an amino acid sequence having a 90% or more homology to the amino acid sequence of (a) or (b) and is capable of binding an anti-Rep antibody specific for a protein having an amino acid sequence of SEQ ID NOs:11 or 12. The present invention further concerns a method of diagnosing MS or a predisposition for MS and a kit for use in such methods.

Provided are a pretreatment method for detecting the number of cells containing Ki-67 protein-positive nuclei using Ki-67 antibody; a method for the detection; a kit to be used in the detection method; and determination of a therapy regimen using the aforesaid method. Attempts were made to activate Ki-67 antigen with the use of an enzyme having been considered as inappropriate for the activation thereof. By pretreating a sample with an enzyme not recognizing the epitope of MIB-1 (a rare cutter enzyme), the antigen activation of Ki-67 antigen was enhanced, while enhancing the antigenicity of other antigens including a cytokeratin too. As a result, a method for more objectively and more universally quantifying Ki-67-positive cells at higher reproducibility, said method comprising isolating cell nuclei from an FFPE section while enhancing the antigenicity and performing a reaction between Ki-67 protein, i.e., the target, existing in the cell nuclei with a fluorescently labeled antibody, has been completed.

The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.